BridgeBio Oncology Therapeutics Inc. Ordinary Shares - Class A BBOT 深 滬
等待開盤 10-09 09:30:00 美东时间
12.025
-0.185
-1.52%
華盛通- 最 高13.18
- 今 開12.33
- 成交量 16.01万股
- 最 低 11.96
- 昨 收 12.21
- 總市值 9.52亿
- 52周最高 13.18
- 市盈率 靜 37.19
- 換手率 0.20%
- 52周最低 8.50
- 委 比 23.37%
- 總股本 7919.67万
- 歷史最高 13.18
- 量 比 1.12
- 振 幅 9.99%
- 歷史最低 8.50
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | Tigress Financial：维持苹果"强烈买入"评级，目标价升至305美元；杰富瑞维持百度"买入"评级，目标价升至157美元
今日重点评级关注：HC Wainwright & Co.：维持Astria Therapeutics"买入"评级，目标价从16美元升至20美元；HC Wainwright & Co.：维持Avalo Therapeutics"买入"评级，目标价从15美元升至25美元
09-18 10:13
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
HC Wainwright & Co. Initiates Coverage On BridgeBio Oncology with Buy Rating, Announces Price Target of $27
HC Wainwright & Co. analyst Robert Burns initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Buy rating and announces Price Target of $27.
09-15 19:58
Oppenheimer Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $23
Oppenheimer analyst Matthew Biegler initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $23.
09-04 20:52
BBOT to Participate in Upcoming September Investor Healthcare Conferences
BridgeBio Oncology Therapeutics (BBOT) announced that members of its leadership team will participate in two investor conferences in September: the Cantor Global Healthcare Conference on September 4 and the Morgan Stanley Global Healthcare Conference on September 8. Both events will include Fireside Chats and investor meetings in New York. Live webcasts and replays will be available on the "Investors" page of the BBOT website, with replays access...
08-20 12:00
Wedbush Initiates Coverage On BridgeBio Oncology with Outperform Rating, Announces Price Target of $25
Wedbush analyst David Nierengarten initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Outperform rating and announces Price Target of $25.
08-18 22:29
